David Wages

Pharmacokinetic study of FFP photochemically treated with amotosalen (S‐59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin

BACKGROUND : To date, no clinical trials have characterized FFP infusion efficacy, and infusion still carries infectious risk. This single‐blinded crossover study compared postinfusion kinetics of FVII in photochemically treated FFP to standard FFP.

Fresh frozen plasma prepared with amotosalen HCl (S‐59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies

BACKGROUND: Photochemical treatment (PCT) with amotosalen HCl (S‐59) was developed to inactivate pathogens and white blood cells in plasma (PCT‐FFP) used for transfusion support.

Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients

BACKGROUND: A randomized, double‐blind trial is reported of the clinical efficacy of red blood cells (RBCs) treated for pathogen inactivation with S‐303, a synthetic labile alkylating agent.

Viability of red cells prepared with S-303 pathogen inactivation treatment

BACKGROUND: A nucleic acid–targeted pathogen inactivation process with S‐303 was developed to treat red blood cells (RBCs).

Structural characterization and functional effects of a circulating heparan sulfate in a patient with hepatocellular carcinoma

A circulating anticoagulant was isolated from the plasma of a 42‐year‐old man with cirrhosis and hepatocellular carcinoma who had an unusual coagulation test profile. The patient developed a fatal coagulopathy, unresponsive to protamine therapy or plasma exchange following liver biopsy. However, at presentation, routine hemostasis assays were normal. The patient had mucocutaneous bleeding but the sole laboratory abnormality was a prolonged thrombin time (TT = 99 s, normal 25–35 s). Protamine titration indicated activity equivalent to a heparin concentration of 6–7 U/ml. Antithrombin III (AT III) antigen and activity were markedly elevated. The anticoagulant activity, purified from plasma by DEAE chromatography, was identified as a glycosaminoglycan (GAG). GAG anti‐thrombin activity was completely abolished by heparin lyase III. Based on the degree of sulfation and HPLC pattern, the GAG was classified as heparan sulfate. Low levels (4 μM) of purified GAG markedly prolonged the TT (>120 s) but not the activated partial thromboplastin time (PTT) (31.4 s). In a Factor Xa assay, the GAG exhibited a potency equivalent to 0.06 U of low molecular weight heparin per nmol of uronic acid. Patients with endogenous circulating glycosaminoglycans can present with unusual laboratory coagulation test profiles. These reflect complex dysfunction of hemostasis, leading to difficulty in providing diagnosis and effective care. Am. J. Hematol. 58:285–292, 1998.

Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies: PCT-FFP FOR COAGULATION FACTOR DEFICIENCIES

BACKGROUND: Photochemical treatment (PCT) with amotosalen HCl (S‐59) was developed to inactivate pathogens and white blood cells in plasma (PCT‐FFP) used for transfusion support.

Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation

BACKGROUND: Photochemical treatment (PCT) with amotosalen HCl (S‐59) was developed to inactivate pathogens and white blood cells in plasma (PCT‐FFP) used for transfusion support.